Xlife Sciences AG Announces VERAXA Biotech's Planned NASDAQ Listing

Xlife Sciences AG has revealed plans for its portfolio company, VERAXA Biotech AG, to be listed on the NASDAQ Stock Market in 2025. The decision was made unanimously during the Board Meeting on December 13, 2024. The listing will be supported by a consortium of experienced partners and institutional investors.

VERAXA Biotech AG, located in Switzerland with R&D operations in Germany, focuses on advanced antibody drug candidates and bispecific T cell engagers. These innovations hold promise for significant advancements in cancer treatment and have spurred recent industry interest in licensing and acquisitions.

Oliver R. Baumann, CEO of Xlife Sciences, highlighted the strategic nature of this move to accelerate VERAXA's growth and enhance its therapeutic offerings. The merger of Velabs Therapeutics and Araxa Biosciences led to the creation of VERAXA in 2021, facilitating the expansion of its pipeline through organic growth, partnerships, and acquisitions. In 2024, VERAXA introduced its BiTAC technology, aimed at improving cancer therapy safety and efficacy.